论文部分内容阅读
目的:比较脂必妥与洛伐他汀治疗高脂血症的疗效。方法:高脂血症病人30例(男性18例,女性12例,年龄60±7a)服用脂必妥3片(0.35g/片),po,tid,连续4wk;另30例(男性16例,女性14例,年龄55±8a)服用洛伐他汀片(20mg/片),Po,qd,连续4wk。结果:脂必妥组降低血TC,TG,AI及升高HDL-ch的总有效率分别为77％,63％,75％,64％;洛伐他汀组分别为79％,60％,73％,65％,组间比较无显著差异。两组均仅有轻微不良反应。结论:脂必妥与洛伐他汀治疗高脂血症的疗效及安全性均相似。
OBJECTIVE: To compare the efficacy of lipid and lovastatin in the treatment of hyperlipidemia. Methods: 30 patients with hyperlipemia (18 males and 12 females, age 60 ± 7a) received 3 doses of Lipid (0.35g / tablet) for 4 weeks. Another 30 patients (16 males , 14 females, age 55 ± 8a) taking lovastatin tablets (20mg / tablet), Po, qd, continuous 4wk. Results: The total effective rates of lipid, TG, AI and HDL-ch in patients receiving lipopeptin were 77%, 63%, 75% and 64%, respectively; those in lovastatin group were 79%, 60% and 73% %, 65%, no significant difference between groups. Both groups had only mild adverse reactions. Conclusion: The efficacy and safety of lipid and lovastatin in the treatment of hyperlipidemia are similar.